Menu
FDA DECISION ·
Revtorpyk + fulvestrant
gedatolisib with fulvestrant, with or without palbociclib · Celcuity
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation, after progression on or following at least one endocrine therapy line in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
The label creates a targeted option in a population defined by the absence of a detected PIK3CA mutation. VIKTORIA-1 studied two gedatolisib combinations against fulvestrant.
What research teams should watch
A negative molecular result needs a traceable test report and adequate specimen. Keep the two experimental regimens separate in safety and efficacy reporting.
Clinical operations takeaway
Give sites separate ways to record a documented negative result, an inadequate specimen, and a test that was never completed. Define who follows up and what the monitor checks for each status.
Plan biomarker screening and specimen workflowsPRIMARY RECORDS